Full-Time

Staff Scientist

Chemistry

Cellanome

Cellanome

51-200 employees

Automated platform for live single-cell assays

Compensation Overview

$140k - $200k/yr

+ Stock options

Foster City, CA, USA

In Person

PhD

Category
Biology & Biotech (1)
Required Skills
Medicinal Chemistry

Get referred to Cellanome

See people who can refer or advise you

Requirements
  • A PhD in Chemistry, Chemical Engineering, Materials Engineering, Bioengineering, or a related scientific discipline, with a minimum of 5 years of relevant experience.
  • Extensive knowledge of biomolecule synthesis and characterization and bioconjugation chemistries.
  • Hands-on experience with surface conjugation or particle-based encapsulation of small molecules, proteins, peptides, or DNA.
  • Experience in drug screening, controlled drug release, or drug delivery.
  • Experience with materials characterization techniques including ultraviolet-visible spectroscopy, high-performance liquid chromatography or ultra-performance liquid chromatography, liquid chromatography–mass spectrometry, nuclear magnetic resonance, Fourier-transform infrared spectroscopy, fluorescence assays, or colorimetric assays.
  • Experience with synthesis and characterization of polymer- or lipid-based microparticles or nanoparticles.
  • Ability to perform the essential duties of the position with or without reasonable accommodations.
  • Ability to stand for extended periods at a laboratory bench, lift up to 20 pounds for approximately 15% of the typical working day, perform specified hand and arm movements, and comply with personal protective equipment requirements.
Responsibilities
  • Develop novel chemistries or bioconjugation strategies for the consumable product line.
  • Develop strategies for immobilization or encapsulation of key reagents on surfaces or in particles.
  • Perform characterization of materials and biomaterials using analytical techniques.
  • Support chemistry process development and quality-control development.
  • Document and analyze experimental data accurately and thoroughly and communicate results within and across teams.
  • Follow laboratory safety protocols and maintain a clean and organized work environment.
  • Work closely with the research and technology development team and process development team members.
Desired Qualifications
  • Experience in surface characterization techniques.
  • Experience in medicinal chemistry.
  • Experience with biocompatibility evaluation of biomaterials.

Cellanome provides an automated platform for live-cell phenotypic and functional assays that analyze single cells at scale. It runs high-throughput experiments that integrate with existing lab workflows, collecting multi-parameter data and allowing iterative testing under different conditions. The system emphasizes single-cell granularity, scalable data collection, and easy assay customization without major process changes. Its goal is to help life sciences, medical research, pharmaceutical, and biotech teams gain deeper cellular insights to accelerate discovery through a platform-as-a-service model.

Company Size

51-200

Company Stage

Series C

Total Funding

$276.9M

Headquarters

Foster City, California

Founded

2020

Get referred to Cellanome

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Psomagen added the R3200 on March 26, 2026, validating external demand.
  • Cellanome showcased live-cell analysis marrying imaging and sequencing at AGBT 2026.
  • Cellanome raised $75.9 million on June 22, 2026, extending runway.

What critics are saying

  • 10x Genomics and other single-cell vendors already dominate adjacent workflows.
  • Cellanome still lacks proof of broad customer adoption beyond Psomagen and conferences.
  • If 2026 spending misses hardware sales, the platform becomes an expensive science project.

What makes Cellanome unique

  • Cellanome links longitudinal live-cell imaging to single-cell transcriptomics from the same cells.
  • Its CellCage micro-3D-printed enclosures isolate cells while drugs and antibodies flow.
  • R3200 captures morphology, phenotype, and RNA on identical live cells.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Stock Options

401(k) Retirement Plan

Flexible Work Hours

Growth & Insights and Company News

Headcount

6 month growth

1%

1 year growth

58%

2 year growth

0%
U.S. Securities and Exchange Commission
Jul 17th, 2026
EDGAR Filing Documents for 0000905148-26-003005

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231Type: D | Act: 33 | File No.: 021-588010 | Film No.: 261104659

Intelligence360 News
Jul 17th, 2026
Cellanome files to raise $75.9M for live-cell imaging and single-cell transcriptomics platform

Cellanome has filed a notice with the US Securities and Exchange Commission to raise up to $75.9 million in new funding. The filing was made under Regulation D of the Securities Act of 1933, which allows companies to sell securities without full registration. The company develops technologies that combine longitudinal live-cell imaging with single-cell transcriptomics from the same cells. This approach enables scientists to capture cellular dynamics over time and connect cellular behaviour with molecular state. Researchers can access Cellanome's technology by implementing its R3200 platform in their laboratories, using its assay services, or collaborating with the company's scientists on new applications.

The Business Journals
Jan 30th, 2024
Peninsula startup with Illumina roots lands $150 million to peer deeper into cells

A Peninsula startup launched by top former Illumina execs raises $150 million to help researchers see what happens when cells dance with each other.

The Business Journals
Dec 8th, 2021
Former Illumina execs, Grail co-founder raise $21M for biotech startup

Biotech A-listers have come together to launch a new venture. What's it targeting? They're not saying.